The expression and clinical significance of microRNA-1258 and heparanase in human breast cancer

Clinical Biochemistry

Volumn 46, Issue 10-11, 2013, Pages 926-932

  Tang, Dabei ^a   Zhang, Qingyuan ^a,b   Zhao, Shu ^a   Wang, Jincai ^a   LU, Kangping ^a   Song, Ying ^a   Zhao, Ling ^a   Kang, Xinmei ^a   Wang, Jingxuan ^a   Xu, Shanqi ^a   Tian, Lantian ^c  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Oncobiology Key Lab of Heilongjiang Common Institution of Higher Learning   (China)

^c THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

BC; BMBC; Breast cancer; FFPE; Heparanase; HPSE; HS; IDC; MicroRNA; MiR 1258; MiRNAs; NSCLC; OS; QRT PCR; RFS; Serum

Indexed keywords

HEPARANASE; MICRORNA; MICRORNA 1258; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER PROGNOSIS; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; UPREGULATION;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONIDASE; HUMANS; LYMPHATIC METASTASIS; MICRORNAS; RNA, NEOPLASM; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84886087245     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.01.027     Document Type: Article

References (40)

1. He J., Zhao P., Chen W. Chinese cancer registry annual report, 2011 2011, Military Medical Science Press, Beijing. 1st ed.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
3. Duffy M.J. Role of tumor markers in patients with solid cancers: a critical review. Eur J Intern Med 2007, 18:175-184.
4. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
5. de Planell-Saguer M., Rodicio M.C. Analytical aspects of microrna in diagnostics: a review. Anal Chim Acta 2011, 699:134-152.
6. Brase J.C., Wuttig D., Kuner R., Sultmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 2010, 9:306.
7. Reid G., Kirschner M.B., van Zandwijk N. Circulating micrornas: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2011, 80:193-208.
8. Wang L., Wang J. Microrna-mediated breast cancer metastasis: from primary site to distant organs. Oncogene 2012, 31:2499-2511.
9. Shi M., Liu D., Duan H., Shen B., Guo N. Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis. Cancer Metastasis Rev 2010, 29:785-799.
10. Greene S.B., Herschkowitz J.I., Rosen J.M. Small players with big roles: micrornas as targets to inhibit breast cancer progression. Curr Drug Targets 2010, 11:1059-1073.
11. Zhang L., Sullivan P.S., Goodman J.C., Gunaratne P.H., Marchetti D. Microrna-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res 2011, 71:645-654.
12. Liu H., Chen X., Gao W., Jiang G. The expression of heparanase and microrna-1258 in human non-small cell lung cancer. Tumour Biol 2012, 33:1327-1334.
13. Schmidt E.P. The expanding appreciation of heparanase in human disease. Neurosci Lett 2012, 511:1-3.
14. Levy-Adam F., Ilan N., Vlodavsky I. Tumorigenic and adhesive properties of heparanase. Semin Cancer Biol 2010, 20:153-160.
15. Ilan N., Elkin M., Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006, 38:2018-2039.
16. Arvatz G., Shafat I., Levy-Adam F., Ilan N., Vlodavsky I. The heparanase system and tumor metastasis: is heparanase the seed and soil?. Cancer Metastasis Rev 2011, 30:253-268.
17. Vlodavsky I., Elkin M., Abboud-Jarrous G., Levi-Adam F., Fuks L., Shafat I., et al. Heparanase: One molecule with multiple functions in cancer progression. Connect Tissue Res 2008, 49:207-210.
18. Theodoro T.R., de Matos L.L., Sant Anna A.V., Fonseca F.L., Semedo P., Martins L.C., et al. Heparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasis. Neoplasia 2007, 9:504-510.
19. Zcharia E., Metzger S., Chajek-Shaul T., Friedmann Y., Pappo O., Aviv A., et al. Molecular properties and involvement of heparanase in cancer progression and mammary gland morphogenesis. J Mammary Gland Biol Neoplasia 2001, 6:311-322.
20. Cohen I., Pappo O., Elkin M., San T., Bar-Shavit R., Hazan R., et al. Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer 2006, 118:1609-1617.
21. Zhang L., Sullivan P., Suyama J., Marchetti D. Epidermal growth factor-induced heparanase nucleolar localization augments DNA topoisomerase I activity in brain metastatic breast cancer. Mol Cancer Res 2010, 8:278-290.
22. Maxhimer J.B., Quiros R.M., Stewart R., Dowlatshahi K., Gattuso P., Fan M., et al. Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery 2002, 132:326-333.
23. Vlodavsky I., Beckhove P., Lerner I., Pisano C., Meirovitz A., Ilan N., et al. Significance of heparanase in cancer and inflammation. Cancer Microenviron 2012, 5:115-132.
24. Zhang W., Yang H.C., Wang Q., Yang Z.J., Chen H., Wang S.M., et al. Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis. Anticancer Res 2011, 31:3423-3428.
25. Wang G.B., Zhou X.Y., Wang X.Q. Relationship between serum heparanase and microscopic venous invasion in patients with hepatocellular carcinoma. Am J Clin Pathol 2010, 134:242-248.
26. Quiros R.M., Rao G., Plate J., Harris J.E., Brunn G.J., Platt J.L., et al. Elevated serum heparanase-1 levels in patients with pancreatic carcinoma are associated with poor survival. Cancer 2006, 106:532-540.
27. Finak G., Sadekova S., Pepin F., Hallett M., Meterissian S., Halwani F., et al. Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res 2006, 8:R58.
28. Thomson T.A., Zhou C., Ceballos K., Knight B. Tissue microarray for routine clinical breast biomarker analysis. The British Columbia cancer agency 2008 experience. Am J Clin Pathol 2010, 133:909-914.
29. Qi L., Bart J., Tan L.P., Platteel I., Sluis T., Huitema S., et al. Expression of mir-21 and its targets (pten, pdcd4, tm1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer 2009, 9:163.
30. Doweck I., Kaplan-Cohen V., Naroditsky I., Sabo E., Ilan N., Vlodavsky I. Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia 2006, 8:1055-1061.
31. Heneghan H.M., Miller N., Lowery A.J., Sweeney K.J., Newell J., Kerin M.J. Circulating micrornas as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010, 251:499-505.
32. Schrauder M.G., Strick R., Schulz-Wendtland R., Strissel P.L., Kahmann L., Loehberg C.R., et al. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One 2012, 7:e29770.
33. Wu X., Somlo G., Yu Y., Palomares M.R., Li A.X., Zhou W., et al. De novo sequencing of circulating mirnas identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med 2012, 10:42.
34. Wang B., Zhang Q. The expression and clinical significance of circulating microrna-21 in serum of five solid tumors. J Cancer Res Clin Oncol 2012, 138:1659-1666.
35. Zen K., Zhang C.Y. Circulating micrornas: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2012, 32:326-348.
36. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al. Characterization of micrornas in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
37. Wang F., Zheng Z., Guo J., Ding X. Correlation and quantitation of microrna aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol 2010, 119:586-593.
38. Zcharia E., Jia J., Zhang X., Baraz L., Lindahl U., Peretz T., et al. Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS One 2009, 4:e5181.
39. Imada T., Matsuoka J., Nobuhisa T., Okawa T., Murata T., Tabuchi Y., et al. Cox-2 induction by heparanase in the progression of breast cancer. Int J Mol Med 2006, 17:221-228.
40. Cohen-Kaplan V., Doweck I., Naroditsky I., Vlodavsky I., Ilan N. Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res 2008, 68:10077-10085.